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Abstract
The understanding of protein–protein interactions is crucial in order to generate a second level of functional genomic
analysis in human disease. Within a cellular microenvironment, protein–protein interactions generate new functions that can
be deﬁned by single or multiple modes of protein interactions. We outline here the clinical importance of targeting of the
Nme-1 (NDPK-A)–Prune-1 protein complex in cancer, where an imbalance in the formation of this protein–protein complex
can result in inhibition of tumor progression. We discuss here recent functional data using a small synthetic competitive cell-
permeable peptide (CPP) that has shown therapeutic efﬁcacy for impairing formation of the Nme-1–Prune-1 protein complex
in mouse preclinical xenograft tumor models (e.g., breast, prostate, colon, and neuroblastoma). We thus believe that further
discoveries in the near future related to the identiﬁcation of new protein–protein interactions will have great impact on the
development of new therapeutic strategies against various cancers.
Therapeutic potential of CPP
In human cells, protein–protein interactions (PPIs) have
been estimated to range from 14,000 binary interactions to
over 650,000 multi-component interactions, and the
detailed deﬁnition of PPI networks has provided new
insight into many protein functions [1]. Following dysre-
gulation of several protein complexes involved in PPIs,
inhibition of speciﬁc complexes has been shown to repre-
sent an attractive therapeutic strategy for several pathologic
conditions, including cancers (see databases of Kyoto
Encyclopedia of Genes and Genomes [KEGG] of cancer;
http://www.genome.jp/kegg/disease/cancer.html).
To date, improvements in the technologies aimed at the
detection of protein structures have produced different
synthetic PPI inhibitors that can target speciﬁc PPIs and
affect their downstream signaling cascades [2, 3]. Indeed,
PPIs have been shown to have roles in the regulation of
fundamental intracellular processes, including the functions
of cell-cycle proteins that are crucial for cell division. An
example of the importance of these protein complexes can
be seen for the cyclin-dependent kinases family (i.e.,
cdk1–8) and their corresponding cyclin proteins (cyclinA-
I). Overall, these proteins are ﬁnely regulated by PPIs
during the cell cycle, in mitosis. The cdk proteins alone do
not show any kinase activity, but instead they acquire the
ability to phosphorylate intracellular proteins when in
association with speciﬁc cyclin partners. These interactions,
in turn, generate protein complexes with additional func-
tions that can drive the cell cycle, and then promote cell
division [4].
PPIs are also of importance in the regulation of cell
apoptosis. The proteins involved here thus include those
that are active during protein shuttling from the nucleus to
the cytoplasm. One of the most important coordinators of
cell apoptosis is the tumor suppressor protein TP53,
whereby its interactions with various binding partners
control a spectrum of intracellular actions. In this context,
the E3-ubiquitin-ligase Mdm2 (murine double minute 2;
human homolog hdm2) has been shown to be essential for
the regulation of growth-suppressive TP53 functions
through modulation of TP53 polyubiquitination and
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proteosomal degradation [5]. In turn, TP53 can activate
Mdm2 at the transcriptional level, thus promoting an
autoregulatory feedback loop [6]. In addition, the binding of
TP53 to the anti-apoptotic Bcl2 family members prevents
their interactions with pro-apoptotic proteins (e.g., BCL2
associated X, or Bax; alternatively known as BCL2
antagonist/killer 1, or Bak), which results in inhibition of
their pro-apoptotic effects in mitochondria [7].
Furthermore, several more PPIs that are directly involved
in tumor progression have been described, which include
TP53 and Mdm2 in tumors that show overexpression of
Mdm2, thus resulting in reduction of the anti-neoplastic
activity of TP53. Here, recent studies on characterization of
the binding sites between Mdm2 and TP53 have allowed
mimetic small molecules to be developed, which are also
known as “Nutlins” (e.g., cis-imidazoline analogs) [8].
Additional analogs have been described that can bind
Mdm2 within the TP53-binding pocket in a competitive
manner, thus further inhibiting the complex formation and
enhancing the TP53 signaling pathway [8].
Here we describe another intracellular cytoplasmic PPI
that results in a physical interaction between the Nme-1
(also known as NDPK-A) and Prune-1 proteins. This
complex has been shown to be associated with cancer
aggressiveness and poor patient prognosis. The Nme-
1–Prune-1 interaction complex has been reported to induce
cell migratory properties and metastatic dissemination in
several tumor malignancies [9]. Here, we review studies
related to the formation of the Nme-1–Prune-1 complex
in vitro, and in particular to the development and use of a
small synthetic competitive cell-permeable peptide (CPP)
that illustrates the therapeutic beneﬁts of impairing the
interactions between the Nme-1 and Prune-1 proteins in
adult and pediatric solid tumors (e.g., breast, prostate and
colorectal tumors, and neuroblastoma) [10, 11].
Genetic interactions between Nme-1 and Prune-1 were
ﬁrst reported in Drosophila melanogaster, where both
homozygous and hemizygous Prune (Pn) mutants that are
responsible for the brownish-purple “prune” eye color were
shown to be lethal in the presence of just a single mutation
(i.e., P97S substitution) in the Nme-1 protein (the NDPK-A
orthologue; alternatively known as awd, abnormal wing
disks gene). These double mutants die at the second to third
larval instar stage due to abnormal development of meso-
derm and central-nervous-system-like cells [12, 13]. Inter-
estingly, this P97S awd mutant can still bind to the Prune-1
protein, while the interaction between Prune-1 and awd is
impaired in the presence of the S120G awd mutant protein
[14]. The lethal interaction was hypothesized be due to
neomorphic mutations that caused alterations during the
GTP and GDP switch mediated by the awd protein in its
regulation of intracellular GTPases and GTPase-activating
proteins [15].
Of particular importance, the ﬁrst evidence in mammals
of Nme-1 and Nme-2 (also known as NDPK-B) and Prune-
1 as co-expressed proteins arose from embryonic tissues
within the central nervous system [16]. Indeed, both of the
NM23-M1 and PRUNE-M1 proteins (i.e., murine homologs
of human Nme-1 and Prune-1, respectively) showed the
same spatio-temporal expression patterns in several regions
of the developing nervous system (from E10.5 to adult-
hood). This thus suggested fundamental functions for
NM23-M1 and PRUNE-M1 during the cell proliferation,
migration and differentiation processes that occur in the
development of the brain and cerebellum [16]. An addi-
tional role of the complex between Nme-X1 and Prune-X1
(i.e., Xenopus homolog proteins) was reported for Müller
gliogenesis during Xenopus retinal development, which
thus indicated an important role for Nme-1 and Prune-1
during the development of the retina and in eye morpho-
genesis [17]. Nme-1 was ﬁrst identiﬁed as having an anti-
metastatic activity in human through differential colony
hybridization studies that were performed on different cell
lines derived from a murine melanoma (K-1735 cells) that
showed varying metastatic potential [18]. The gene here
was originally named as “Non-metastatic 23” (NM23), and
then Nm23-M1 (i.e., murine homolog gene) after the dis-
covery of a second Nm23 gene that was deﬁned as Nm23-
M2 [19]. Later, the human counterparts Nm23-H1 and
Nm23-H2 were identiﬁed through cDNA library screening
in human ﬁbroblasts, with these genes also referred as
NDPK-A and NDPK-B (i.e., NME1, NME2, respectively)
[20].
Of note, Nme-1 was reported as being overexpressed in
several tumorigenic cell lines, which included melanoma,
breast and oral squamous cell carcinomas and lymphomas,
and to reduce cell motility in vitro and inhibit metastatic
dissemination in vivo [18, 21–23]. Notwithstanding these
reports, high Nme-1 protein levels have also been positively
correlated to poor patient prognosis, with their expression
levels associated with low overall survival for patients
affected by osteosarcoma and hematological tumors [24,
25]. These different behaviors of Nme-1 in several tumors
can be explained in part by its multiple functions (i.e.,
nucleotide diphosphate kinase: NDPK [26] histidine protein
kinase [27, 28]; 3′−5′ exonuclease activity [29], and also by
its potential to bind to different interactor proteins that are
involved in several signaling pathways, including G-protein
complexes and their functional activation, mitogen-
activated protein kinase, and the transforming growth
factor-β signaling cascade, and its association with cytos-
keleton proteins (e.g., β-tubulin) [30].
Prune-1 belongs to the phosphoesterase DHH protein
family and it has also been shown to be positively regulated
by Nme-1 [9]. Of importance, Prune-1 has an exopoly-
phosphatase activity (PPX/PPAse) that shows higher
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afﬁnity for short-chain over long-chain inorganic polypho-
sphates [31]. This Prune-1 PPX/PPase activity was shown
to be negatively inﬂuenced through Prune-1 binding with
Nme-1, thus further conﬁrming that the Nme-1–Prune-1
complex might acquire a different function in terms of
inﬂuencing the pool of inorganic polyphosphate levels in
cellular compartments [31].
To date, literature data that highlight the association
between dysregulated Prune-1 activity and tumor progres-
sion have been described for patients with highly metastatic
breast [32], gastric, esophageal [33], non small-cell
lung [79], and colorectal [34] cancers. The binding of
Prune-1 to Nme-1 and Nme-2 was also conﬁrmed using co-
immunoprecipitation assays in human breast cancer cells
(i.e., MDA-MB-435 cells) [35]. In mammalian cells,
alterations in the equilibrium of the Nme-1–Prune-1 inter-
action complex are responsible for the switch to patholo-
gical conditions (i.e., cancer) through effects on speciﬁc-
related protein networks [36, 37]. Thus, the Nme-1 and
Prune-1 protein interaction might help to explain the dual
role of Nme-1 in its actions as a metastasis-suppressing or
metastasis-promoting protein, as ﬁrst described for the Nme
proteins [30].
Studies on the regions of interaction between Nme-1
and Prune-1 have ﬁnely mapped the region of their
interaction through afﬁnity chromatography approaches
and Western blotting analyzes in human breast cancer cell
lines. These studies indicated that the carboxyl-terminus
(C-term) domains of both of these proteins are responsible
for their interaction [35]. Then, a three-dimensional model
of the C-term domain of Prune-1 (C-term-Prune-1) was
obtained through nuclear magnetic resonance spectro-
scopy studies combined with homology modeling and
molecular dynamics approaches. This tertiary structure of
C-term-Prune-1 provided further insight into the amino-
acid regions that are involved in the interaction between
Prune-1 and Nme-1 and Nme-2 [10] . Interestingly, these
data reported the presence of two globular domains in the
Fig. 1 (A) Sequence alignment of the region of the human Nme-1, -2,
-3, -4 and -6 proteins (also known as NDPK-A, -B, -C, -D,-F) that are
mainly involved in the interactions with the Prune-1 protein (residues
115 to 129), illustrating their conservation with a high degree of
identity and homology across their isoforms. Within this carboxyl-
terminus region of these Nme proteins, serines 120, 122 and 125 are
also conserved (black boxes). These residues show high probability
scores for phosphorylation mediated by intracellular casein kinases I
and II, and their phosphorylation is necessary for the binding of Nme-1
and Nme-2 (NDPK-A, -B) with Prune-1. (B) Alignament of the
sequence region of the carboxyl-terminus domain of Prune-1 (residues
384-453), which is involved in the binding to Nme-1, shows the
conservation through evolution across different vertebrates with a high
degree of sequence identity and homology. The amino-acid residues
that are mainly responsible for the interaction between Prune-1 and
Nme-1 are shown in black boxes (i.e., D388, C419, D422). These
three residues lie within the proline-rich motif of Prune-1 and are
shared between species (vertebrates, chordates), excluding Xenopus
laevis and Zebraﬁsh (with potential divergency in tetrapods), but
including the Fugu rubripes (Fugu ﬁsh) genome. The region from 420
to the end of Prune-1 (amino acid 453) is responsible for its dimer-
isation, which has been reported to interact with the hexameric form of
Nme-1 (NDPK-A) [41]. These sequence alignaments were realized
using the ClustalX 2.1 software.
Therapeutic applications in cancer
N-terminus region (DHH, DHHA2) that are responsible
for the Prune-1 enzymatic activities [10]. An intrisically
disordered domain was then identiﬁed in Prune-1 that
begins at amino-acid residue 371 and contains two stret-
ches with a propensity for helix formation, and a small
globular region that mediates Prune-1 binding to Nme-1
and Nme-2 [10]. Together with site-direct mutagenesis
approaches, these mapping data identiﬁed the D388 and
D422 residues of Prune-1 as the most conserved amino
acids of the C-term-Prune-1 region that is involved in
Prune-1 binding to Nme-1. In summary here, through
alignments performed with ClustalX 2.1, these regions of
interaction between the Nme-1, Nme-2, Nme-3, Nme-4,
and Nme-6 (NDPK-A, NDPK-B, NDPK-C, NDPK-D,
NDPK-F) and Prune-1 proteins are highly conserved in
these amino-acid sequences in human (Fig. 1a).
The Prune-1 region of interaction with Nme-1 was then
also shown to retain a region with a high degree of simi-
larity across different species (Fig. 1b). These data further
implied that this functional interaction that leads to the
complex formation must have a fundamental role in cell
physiology (e.g., potentially regulating cell migration) as it
has been maintained in all vertebrates through natural
selection. Indeed, the D388A and D422A Prune-1 mutant
proteins (where the D388 and D422 residues of Prune-1
were mutated to alanine) only weakly interacted with Nme-
1 and did not induce any pro-migratory phenotype when
overexpressed in mammalian cells (e.g., HEK-293T cells)
[10]. These data are of particular importance for the corre-
lation of Nme-1–Prune-1 protein complex formation with a
pro-migratory phenotype, and they further strength the
functional consequences, considering that this is a function
that would have been positively selected for through
evolution.
Furthermore, nuclear magnetic resonance spectroscopy
has allowed the Nme-1 and Prune-1 interaction to also be
observed in different human cells (e.g., HEK-293T, SH-
SY5Y cells), thus conﬁrming the formation of a high
molecular weight complex between Nme-1 and Prune-1
directly in human cell lysates [38]. Thus, single-point
mutations of Nme-1 that are known to alter its biochemical
activity (e.g., P96S, S120G) were shown to negatively
affect the Nme-1 interaction with Prune-1, and also cell
motility. This thus conﬁrmed that the loss of the activity of
Nme-1 mutant proteins (e.g., NDPK-A-P96S, NDPK-A-
S120G mutants) was mainly due to their lack of binding to
Prune-1 [38]. Once again, the Nme-1–Prune-1 protein
complex was shown to have a fundamental role in these
neuroblastoma tumorigenic cells, thus further conﬁrming its
role in cancer progression.
Through bioinformatic analyzes of the S(p)-x-x-S con-
sensus sequence for casein kinase I and II (CKI, CKII), the
Fig. 2 (A) Left: Sequence region of the carboxyl-terminus domain of
the Nme-1 (NDPK-A) protein that is responsible for its interaction
with Prune-1 (residues 115-128). This is higly conserved across dif-
ferent species (e.g., Homo sapiens, Drosophila melanogaster, Mus
musculus, Xenopus leavis, Zebraﬁsh) with a high degree of homology
and identity. Right:The amino acids of the carboxyl-terminus domain
of the Nme-1 protein (N115-E128; red box) used for the development
of the competitive cell-permeable peptide (CPP) that was designed to
impair the Nme-1–Prune-1 interaction complex. The selected sequence
contains the three serine residues that are important for phosphoryla-
tion mediated by Casein Kinases I and II (i.e., S120, S122, S125). This
phosphorylation is necessary for the interaction of Nme-1 with Prune-
1. This sequence was then fused to the trans-activating protein region
of the human immunodeﬁciency virus (blue box) for the generation of
the CPP with adenovirus carrying vector of type V. The sequence
alignament was realized with the ClustalX 2.1 software. (B) Repre-
sentative model showing the intracellular mechanism of action of CPP.
This synthetic CPP can compete with the intracellular Nme-1 (NDPK-
A) protein for phosphorylation on the S120, S122 and S125 residues
mediated by Casein Kinase I and II, thus reducing Nme-1 phosphor-
ylation and impairing Nme-1 binding to the Prune-1 protein. The
treatment with CPP thus impairs the Nme-1–Prune-1 interaction and
results in reduction of tumour progression and metastatic dissemina-
tion for several solid tumours in animal models of cancer (i.e., breast,
prostate and colorectal cancer, and neuroblastoma).
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regions of Nme-1 and Nme-2 from their serine 120 (S120)
to serine 125 (S125) residues were shown to contain can-
didates with high probability scores for phosphorylation
mediated by CKI and CKII, with a perfect match within this
amino-acid region [35, 39]. Among the different isoforms of
CKI, CKIε was reported as the most efﬁcient for phos-
phorylation of Nme-1 using in-vitro kinase assays [35].
These residues (S120, S122, S125) appeared to be respon-
sible for the intracellular interaction of Nme-1 with Prune-1,
and indeed, single point mutations in these amino acid
positions of Nme-1 were independently shown to affect its
interaction with the human Prune-1 protein. Moreover, in-
vitro studies demonstrated that the Nme-1–Prune-1 inter-
action complex was only seen when Nme-1 had been pre-
viously phosphorylated by CKI [35]. These ﬁndings
suggested that CK-mediated phosphorylation of Nme-1 is a
physiological condition that is necessary for this PPI within
cells in a particular cellular environment.
Furthermore, phosphorylation of Nme-1 by CKI inﬂu-
ences its oligomerisation status, with the recombinant Nme-
1 protein showing an increase in its hexameric structure
upon CKI phosphorylation (53.6% hexamer, 42.2% trimer,
and 4.1% dimer). Further, addition of the recombinant
Prune-1 protein during CK-induced phosphorylation of
Nme-1 showed that Prune-1 dimers can bind to the hex-
americ structure of Nme-1 [40]. Altogether, these data
clariﬁed the interaction regions of both Nme-1 and Prune-1
at the molecular level. This, thus conﬁrmed the formation of
a high-molecular-weight complex that included six Nme-1
molecules linked to two Prune-1 protein monomers.
At this time, a competitive cell-permeable peptide (CPP)
that mimics the minimal region of interaction of Nme-1 and
Nme-2 (i.e., amino acids 115–128) was designed to impair
the formation of the Nme-1–Prune-1 complex [35, 38].
Clinical shift mapping was applied to dissect out the
interactions of Nme-1 and CPP with C-term-Prune-1. Here,
the interaction surface, seen as a smaller amino-acid region
within CPP, preserved most of the amino acids that belong
to the residues 387–396 region and a smaller part of the C-
term globular region [10]. Then, in vitro in cells, CPP was
shown to reduce the phosphorylation of Nme-1 mediated by
CKI and CKII, and to subsequently impair the formation of
the Nme-1–Prune-1 complex [35]. For this purpose, the
amino-acid sequences for the Nme-1–Prune-1 interaction
were fused to the trans-activating protein of the cell-
penetrating region of human immunodeﬁciency virus, and
this was used in vitro to conﬁrm its activity within the use of
an adenoviral-carrying vector type V (see Fig. 2a) that can
synthesise this peptide in vivo once it has infected tumori-
genic cells that represented different tumor types. The fol-
lowing paragraphs describe the use of this adenovirus for
therapy in vitro and then in in-vivo preclinical studies in
mouse tumor models.
Breast cancer is the most common malignant disease in
women. Among the major subtypes of breast cancer, basal-
like breast cancer (also known as triple-negative breast
cancer) is the most aggressive and the least sensitive to
standard chemoradiation regimens currently used in clinics
[41]. Overexpression of Nme-1 has been reported in several
metastatic cell lines, and Nme-1 has been described as a
metastasis suppressor in breast cancer [42]. In this context,
Nme-1 has been reported to reduce cell motility when
overexpressed in breast cancer cells [43]. Conversely, high
tissue levels of Nme-1 expression have been shown in
patients with breast cancer, and statistically positive asso-
ciations of high Nme-1 expression and poor overall survival
and relapse-free survival have also been reported [44].
These opposing roles for Nme-1 in metastatic breast cancer
can be partially explained by taking into account the
extracellular Nme-1 protein that was identiﬁed [45, 46].
Interestingly, the Awd (orthologue of Nme-1/ NDPK-A)
protein was also detected in the extracellular environment in
the D. melanogaster model [47]. Indeed, both of the Nme-1
and Nme-2 proteins have been found in culture medium
supernatants collected from breast cancer cell lines [46].
Moreover, these same proteins were also found in the sera
from patients with breast cancer, with higher levels in those
women with metastases, thus suggesting an extracellular
role with a positive correlation to metastatic progression in
breast cancer [46].
Furthermore, secreted extracellular Nme-1 and Nme-2
have also been proposed to have roles in the promotion of
angiogenesis in breast cancer. Indeed, several breast cancer
cell lines have been shown to induce endothelial cell
tubulogenesis through secretion of both Nme-1 and Nme-2
[48], thus resulting in endothelial cell growth and migration
through activation of vascular endothelial growth factor
receptor type 2 and extracellular signal-regulated kinase
[49], or by modulation of the levels of nucleotides in the
tumor vasculature (e.g., increased ATP levels), to promote
the release of vasoactive factors with angiogenic activities.
On the other hand, this metastatic malignant breast cancer
behavior has also been positively associated with clonal
selection ampliﬁcation of the 1q21-q22 chromosomal
region. This common aberration occurs more frequently in
metastatic lesions than in primary lesions, and it is asso-
ciated with short patient overall survival [50, 51] and che-
motherapy resistance [52, 53]. The PRUNE-1 gene is
located on 1q21.3, which is a region that is also ampliﬁed in
advanced breast cancers [54]. Of interest, the over-
expression of Prune-1 was shown for tumors that were also
characterized by higher Nme-1 expression levels [54].
These data suggest that in this set of clonal selected tumors
with ampliﬁcation of the 1q21-22 region and with high
Nme-1 expression levels, the increased Prune-1 levels can
enhance tumor progression and metastatic dissemination.
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Tissue multiple arrays on primary tumor tissues derived
from patients with metastatic breast cancer then conﬁrmed
this hypothesis [9]. Later, the distribution of Prune-1 was
examined in a larger and better-characterized tissue cohort
of invasive breast cancers. Here, the immunoistochemical
analyzes revealed that the strong cytoplasmic immunor-
eactivity for Prune-1 observed in the majority of the breast
cancer tumors tested (54%) was signiﬁcantly correlated
with advanced nodal status (N2-N3 cases) and positive
lymph-node status (P= 0.017), and with distal metastases
(P= 0.029). Overall, the potential application of Prune-1 as
a marker for identiﬁcation of the subsets of patients with
aggressive metastatic breast cancer was deﬁned [32].
The potential to reduce the PPI complex formation
through inhibition of the CK-mediated phosphorylation of
Nme-1 (which is necessary for binding to Prune-1) was
investigated using IC261 (ATP-competitive inhibitor,
selective for CKIδ and CKIε [55]) in breast cancer cell
lines. These data suggested that in a breast cancer cell
model, this inhibition of phosphorylation of Nme-1 by
IC261 can impair the formation of the Nme-1–Prune-1
complex, decrease the Prune-1 PDE enzymatic activity, and
reduce cell migration [35]. Furthermore, and most impor-
tantly, this occurred with greater speciﬁcity in relation to
serine inhibition of phosphorylation. Nonetheless, doubts
were raised about the IC261 speciﬁcity of action against
CKIδ/ε inhibition, as IC261 was also demonstrated to alter
microtubule depolymerization [56]. Then the CPP was
developed that mimicked the region of Nme-1 that is
involved in the interaction with Prune-1, including Ser120,
Ser122, and Ser125. This peptide was used in similar
experiments, and it showed similar efﬁcacy to IC261 [35].
Furthermore, therapeutic properties of CPP were identi-
ﬁed in vitro using breast cancer cell lines and cell pro-
liferation assays [11]. Indeed, block of the Nme-1–Prune-1
interaction using CPP reduced proliferation of breast cancer
cells (i.e., MCF7, MDA-MB-231 cell lines), as measured
using cell index proliferation assays. Of interest, CPP also
inhibited the AKT/ mTOR and NF-kB signaling pathways
in these treated breast cancer cells [11].
In prostate cancer [57], a prognostic role for Nme-1 has
been deﬁned [58]. We reported on a study in a large cohort
where the analysis showed that Nme-1 is a negative prog-
nostic factor for prediction of patient outcome [59]. As the
Nme-1–Prune-1 interaction has been directly correlated to
migratory properties of several tumorigenic cells, the
potential for CPP to impair this complex formation was also
investigated in the PC3 prostate cancer metastatic cell line
[11]. Expression of CPP in PC3 cells was obtained using
adenoviral particles that provided high efﬁciency of infec-
tion, and the CPP block of the binding between Nme-1 and
Prune-1 was assessed in these cells using an afﬁnity chro-
matography approach. Furthermore, CPP was also shown to
impair cell proliferation and induce cell apoptosis in these
PC3 cells (assayed as cell index of proliferation on a real-
time system, and as caspase 3 activity assays, respectively).
Of importance, the inhibition of PC3 cell migration by CPP
was also determined through monitoring cell migration in
real time using the xCELLigence RTCA DP system. These
data showed that in vitro, CPP-treated PC3 cells had
reduced migratory properties compared to control cells
(infected with empty adenoviral particles) [11]. These data
suggested a direct correlation between the Nme-1–Prune-1
interaction complex and enhancement of cell motility also
in prostate cancer metastatic cell lines.
The potential for CPP inhibition of metastases arising
from prostate cancer was then evaluated in vivo using an
orthotopic murine xenograft model of human PC3-Luc cells
(i.e., PC3 cells stable for ﬁreﬂy luciferase expression)
injected into the dorsal prostate of athymic nude mice [11].
This xenograft metastatic model of prostate cancer had been
previously reported to resemble the metastatic behavior of
prostate cancer cells in humans with regard to the devel-
opment of metastases [60]. Thus the potential anti-
metastatic effects of CPP were evaluated by delivery of
adenoviral particles carrying the sequence that encoded
CPP, through tail-vein injections in mice 1 month after
prostate cancer surgical implantation. Two weeks later, the
tumor-bearing mice were sacriﬁced and a decrease in tumor
growth was shown in the CPP-treated mice. Most impor-
tantly, the lungs, liver, and femurs from each mouse were
excised and analyzed using ex-vivo bioluminescence ima-
ging, with suppression of macro-metastases seen for the
CPP-treated group of mice. All of the control tumor-bearing
mice showed macro-metastases in the lungs, liver or femur.
In contrast, among the CPP-treated tumor-bearing mice,
only one (of four) showed macro-metastases in the lungs,
while none of them showed metastases in the liver or femur.
This thus showed that CPP can be effective ffor inhibition
of metastatic dissemination in prostate-cancer-bearing mice
after a single dose of adenoviral particles administration
[11].
Additionally and most importantly, the haematological
status in the CPP-treated mice did not show any variations
for white-blood cell, platelet and erythrocyte total cell
numbers, and there was an absence of kidney and liver
failure, as measured by creatinine and alanine amino-
transferase levels. We also investigated whether CPP
induced apoptosis in non-tumoral cells, using non-tumoral
human embryonic kidney cells (i.e., HEK-293T cells),
where CPP did not activate caspase 3. Altogether, we
conﬁrmed that there were no signs of toxicity of CPP in
normal proliferating cells. This indicates further that the
pro-apoptotic effects of CPP occur only in tumorigenic
cells, thus reinforcing its therapeutic future applications in
metastatic prostate cancer treatment [11].
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In colorectal cancers that develop liver metastases, the
role of Nme-1 in colorectal carcinoma still remains con-
troversial, and its cellular mechanisms in terms of the
metastatic phenotype are not yet fully understood [61]. The
potential association of Nme-1 with liver metastases and
survival in patients with colorectal carcinoma was investi-
gated by performing multiple arrays of primary tissues [62].
Nme-1 expression was signiﬁcantly higher in the colorectal
carcinoma tissues than in the adjacent non-neoplastic
mucosa (P < 0.0001), but it did not correlate with the pre-
sence of liver metastases or patient overall survival [62].
Nme-1 has also been reported to have a signiﬁcant role
in vitro in the reduction of migration of colon cancer cells
(i.e., HT29 cells), and in vivo it was shown to suppress liver
metastases, using xenograft mouse models [63]. Here, the
group of mice injected with Nme-1–overexpressing cells
showed lower liver weights, with fewer metastatic foci
compared to the control mouse group [63].
The role of Prune-1 was also investigated in colorectal
cancer liver metastases, both in vitro and in vivo. To this
end, Prune-1 expression increased cell migration in vitro
using colorectal cancer cell lines that showed high and low
expression levels of their endogenous Prune-1: SW480
and HCT116 cells, respectively [34]. The Prune-
1–knocked-down SW480 (sh-Prune-1-SW480) cells and
Prune-1-overexpressing HCT116 cells were assayed for cell
migration in vitro. These data indicated the pro-migratory
phenotype ascribed to the expression of Prune-1. Of
importance here, the sh-Prune-1-SW480 cells also showed
downregulation of mesenchymal markers (i.e., N-cadherin,
vimentin), and a corresponding upregulation of epithelial
markers (i.e., E-cadherin, Zo-1). These data suggested that
Prune-1 expression is associated with epithelial-to-
mesenchymal transition, which is known to be crucial for
metastasizing to distant organs. These data were also con-
ﬁrmed later in an in-vivo assay where sh-Prune-1-SW480-
luc cells (i.e., stably overexpressing the Fireﬂy luciferase
gene) were injected into the portal vein of NOG/Jic mice.
The luciferase activity in the mice injected with sh-Prune-1-
SW480 was signiﬁcantly lower in comparison with those
injected with ‘scrambled’-SW480 cells. Thus, Prune-1 was
reported to promote liver metastases from colorectal cells
also in vivo, mainly due to the activation of epithelial-to-
mesenchymal transition [34].
We additionally tested the anti-tumorigenic potential of
CPP in colorectal cancer cells in vitro using an adenovirus
delivery system [11]. For this purpose, both HT29 and
SW480 cells were treated with CPP (delivered via the
adenoviral technology), and cell proliferation was deter-
mined using cell index real-time proliferation assays. These
data showed decreased proliferation rates for the CPP-
treated cells compared to the control cells [11]. In addition,
there was a signiﬁcant increase in caspase 3 activity in the
CPP-treated cells, which thus suggested that the anti-
proliferative effects mediated by CPP are also due to
activation of apoptosis in the treated cells [11]. Further-
more, CPP also showed decreased phosphorylated Nme-1
and inhibited the AKT and NF-κB pathways in both the
HT29 and SW480 treated cells, thus deﬁnitively showing
that the anti-proliferative effects of CPP arise from Nme-
1–Prune-1 complex regulation of the signaling cascades of
metastatic colorectal cancer [11]. These data support the
use of CPP for the treatment of animal models of colorectal
cancer and metastasis formation, to conﬁrm its efﬁcacy
in vivo.
Neuroblastoma is the most common embryonal malig-
nancy of the sympathetic nervous system of early childhood
[64]. Here, a single point mutation of Nme-1 that results in a
Ser120-Gly substitution has been reported for 21% of
patients with advanced neuroblastoma, with gain of chro-
mosomal segment 17q21 also seen. The association of these
Nme-1 aberrations with the high metastatic potential of
human neuroblastoma strongly suggests that Nme-1 func-
tions as a metastasis promoter protein [65].
The literature data indicate that overexpression and
S120G mutation of Nme-1 promote neuroblastoma metas-
tases by preventing neuronal differentiation and increasing
neuroblastoma colonization and cell survival, with Nme-1
considered as a potential marker for prediction of clinical
outcome of patients with neuroblastoma [66]. Furthermore,
examination of the serum Nme-1 protein levels in 217
patients with neuroblastoma revealed signiﬁcantly higher
expression levels in patients with neuroblastoma than in
control children. However, in these patients, high serum
Nme-1 levels (≥250 ng/mL) were positively associated with
N-myc ampliﬁcation and negatively correlated with poor
overall survival. These data are of importance, because they
highlight the contribution of the serum Nme-1 protein levels
to the predictions of clinical outcome in children affected by
neuroblastoma [67].
We investigated the role of Nme-1–Prune-1 protein
complex formation in neuroblastoma tumor progression and
metastases [10]. Furthermore, the use of CPP with adeno-
virus delivery was investigated in neuroblastoma cells, to
determine its therapeutic properties in vitro. When the
expression of CPP was driven in neuroblastoma cells,
impairment of the binding between Nme-1 and Prune-1 was
seen, with decreased levels of phosphorylated Nme-1. As a
consequence, a reduction in cell proliferation and induction
of apoptosis were also reported (assessed by cell prolifera-
tion assays and caspase 3 activity measurements, respec-
tively) [10], [11]. Most importantly, CPP also inhibited
cellular motility in vitro in two different neuroblastoma cell
lines (i.e., SH-SY5Y, SHEP cells). The anti-tumorigenic
actions of CPP were also investigated in vivo here, using
heterotopic xenograft mice injected with SH-SY5Y-Luc
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cells (i.e., that expressed the Fireﬂy luciferase gene) pre-
viously infected with the adenoviral particles carrying CPP
or the control (empty adenoviral particles; mock) using in-
vivo biolumuniscence imaging technology. The mice that
received CPP-treated SH-SY5Y-Luc cells showed
decreased tumor burden compared to the control group.
Interestingly, the tumors analyzed from the mice under the
active treatment showed immunoreactivity staining for the
neuronal marker Tuj1 (i.e., neuron-speciﬁc class III β-
tubulin), which is indicative of neuronal differentiation
processes, and caspase-3 activation.
Altogether, these data demonstrated the therapeutic
beneﬁts of the use of CPP in neuroblastoma, where high
expression of Nme-1 has been identiﬁed, together with
Prune-1 expression. These ﬁndings are relevant for the
potential treatment of pediatric neuroblastoma characterized
by chromosome 17q gain and overexpression of Nme-1
[10].
Future perspectives
Genetic interactions between Nme-1 and Prune-1 D. mela-
nogaster orthologue proteins (NDPK-A; AWD; Killer of
Prune) where described by Biggs et al. [68]. Homozygous
and hemizygous Prune-1 mutants were shown to be lethal in
the presence of the P97S mutation in the awd protein, the
Nme-1 orthologue. This genetic interaction has been con-
served at the protein level throughout evolution, mainly in
vertebrates, including Mus musculus, Danio rerio, and
Xenopus laevis [14].
Efforts have been put into the mapping of the amino
acids responsible for the Nme-1–Prune-1 interaction
through nuclear magnetic resonance spectroscopy approa-
ches, aimed at inhibition of this PPI within tumorigenic
cells. Since then, phosphorylation of Nme-1 (on Ser120,
Ser122, and Ser125) was shown to be mediated by con-
sensus region phosphorylation by CKI and CKII [35]. Thus,
targeting these phosphorylation events might represent a
new therapeutic strategy to impair formation of the Nme-
1–Prune-1 complex within tumorigenic cells.
To address this issue, we developed CPP, which mimicks
the minimal region of interaction of Nme-1 with Prune-1,
from amino acids 115 to 129, and thus it contains the crucial
residues that can be phosphorylated by CKI (i.e., S120,
S122, and S125). CPP has been shown to impair the Nme-
1–Prune-1 interaction complex in several tumorigenic cell
lines. As a consequence of this impaired Nme-1–Prune-1
interaction, CPP reduced cell proliferation and cell motility
across a panel of solid tumor cell lines, thus representing a
novel strategy to inhibit tumor progression (Fig. 2b). These
anti-tumorigenic effects have been shown in vitro in breast,
prostate and colorectal tumors, and in neuroblastoma. The
expression of CPP in these tumorigenic cells was achieved
by infection with adenoviral particles carrying the sequence
that encodes CPP fused to the transactivating protein from
human immunodeﬁciency virus. The same approach was
used to investigate the therapeutic effects of CPP in vivo in
xenograft models of prostate and neuroblastoma tumors. In
these in-vivo trials, CPP decreased the metastatic dis-
semination following tumor implantation in nude mice, thus
indicating the potential for application of CPP to inhibition
of metastasis formation in prostate cancer and
neuroblastoma.
Of interest, CPP did not show toxic effects in vitro, as it
did not affect cell proliferation or induce caspase-3–induced
cell apoptosis in non-tumorigenic cells (i.e., HEK-293T,
mouse embryonic ﬁbroblasts [11], thus suggesting its spe-
ciﬁc action against tumorigenic cells. Most importantly,
CPP was administered in the same way in vivo in a
metastasis assay of the orthotopic murine model of meta-
static prostate cancer (i.e., PC3 cell lines stably expressing
ﬁreﬂy luciferase activity). The treated mice did not show
any side effects in terms of haematological parameters, thus
showing the biosafety of CPP also in vivo. However, a
more safe and effective delivery system (e.g., using nano-
liposomes) might overcome the problems of the adenovirus-
based delivery system. Future studies that investigate the
efﬁcacy of a nanoparticle-CPP delivery system could
address novel cancer therapeutic strategies for tumors
requiring ectopic administration (e.g., brain tumors).
However, as CPP is a mimetic peptide of a phosphory-
lated domain of Nme-1, it might impair the interactions of
Nme-1 with several other proteins, and thus impair other
biological functions in cells. Indeed, Nme-1 and Prune-1
have both been described as ‘sticky’ proteins, and the
identiﬁcation of other protein interactors would be useful to
better understand their biochemical functions and their
involvement in tumor metastasis processes. Future studies
will be aimed at gaining deeper insights into the mechan-
isms of proliferation and migration inhibition mediated by
the CPP action in modulating the protein networks
responsible for switching to pathological conditions [70,
36].
Furthermore, in treated tumorigenic cells, CPP also
impaired the AKT/ mTOR and NF-kB pathways, thus also
suggesting a role for the Nme-1–Prune-1 protein complex in
these signaling cascades. Interestingly, both of these path-
ways are involved in the functions of inorganic polypho-
sphates in cells, in terms of cell proliferation and
inﬂammation [71, 72]. Along these lines, Nme-1 was
reported to inhibit the protein phosphatase enzymatic activity
of Prune-1 [31]. Future studies will also be performed to
determine the effects of the Nme-1–Prune-1 protein complex
in terms of its role in the modulation of the levels of inor-
ganic polyphosphates in neural cells, which have already
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been shown to regulate cell signaling through voltage-gated
channels [73] . Furthermore, dissection of the role of inor-
ganic polyphosphates in the mammalian nervous system
would be of special interest, where both the Nme-1 and
Prune-1 proteins and their complex formation have potential
roles during brain and cerebellum development [16].
Moreover, homozygous recessive mutations in Prune-1
have been shown for several families worldwide that are
afﬂicted with microcephaly and PEHO-like syndrome [74,
75]. These gain-of-function mutations result in increased
Prune-1 PPX/PPase activity in all of the mutant Prune-1
proteins, with delays in microtubule polymerization rates
together with interactions with both β-tubulin and α-tubulin
on the mitotic spindle during mitosis, which thus affects the
cell proliferation and migration processes [75]. Of interest,
Nme-1 has also been reported to interact with microtubules
[76] and its biochemical nucleotide diphospho kinase
(NDPK) activity within centrosomes during cell division
has also been described [77, 78]. Of note, IC261 inhibition
of CKI δ/ε, which are responsible for Nme-1 phosphor-
ylation, is also known to impair microtuble depolymeriza-
tion [56]. Altogether, these data suggest an additional role
for the Nme-1–Prune-1 complex during cell division and
mitosis, and so anomalies due to incorrect formation of the
Nme-1–Prune-1 complex in affected children might result
in neural developmental defects in the central nervous
system (e.g., in brain, cerebellum, and optic nerve). To
better dissect out these hypotheses, future studies need to
investigate this potential “lethal interaction” in microcephaly
and PEHO-like syndrome affected patients. This would thus
open a novel scenario in which the therapeutic effects of
CPP can also be investigated in these human genetic neu-
rodevelopmental disorders.
To date, the presence of Nme-1 in the extracellular
compartment “serum” from affected patients has not been
deeply investigated in terms of its diagnostic potential.
Here, extracellular Nme-1 and Prune-1 have been reported
for serum of patients with breast cancer and lung cancer,
respectively [46, 79] . Together with impairment of NF-kB
in CPP-treated tumorigenic cells [11], these ﬁndings sug-
gest a role for the Nme-1–Prune-1 complex also in the
inﬂammation cascade, and subsequently in modulation of
the tumor microenvironment.
In summary, CPP has been shown to impair Nme-
1–Prune-1 protein complex formation and has demonstrated
beneﬁts in terms of cell proliferation and migration,
induction of cell apoptosis, and inhibition of metastatic
dissemination both in vitro and in vivo in different
tumorigenic cells and in xenograft murine models (i.e.,
breast, prostate and colorectal cancers, neuroblastoma).
These data represent a novel therapeutic option for the
treatment of metastastatic dissemination in metastatic
tumors that are characterized by alterations in Nme-1 and
Prune-1 protein levels. However, at this stage, these ﬁrst
analyzes of the therapeutic potential of CPP might only
represent the “tip of the iceberg”.
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